Form 4 for LYEL Lyell Immunopharma, Inc.
Accepted 2025-06-11 00:00:00 ET · period of report 2025-06-09 · accession 0001415889-25-016728 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-11 | 2025-06-09 | LYEL | Shook David | Chief Medical Off | A - Grant | $0.00 | +21.9K | 21.9K | New | $0 |
| D | 2025-06-11 | 2025-06-09 | LYEL | Shook David | Chief Medical Off | A - Grant | $0.00 | +43.8K | 43.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-09 | A | A | 21,900 | $0.00 | 21,900 | D | — | — | (F1) Represents restricted stock units granted under the Issuer's 2021 Equity Incentive Plan ("RSUs"). 25% of the total shares subject to the RSUs will vest on June 9, 2026, and an additional 1/16th of the total shares subject to the RSUs per quarter thereafter, subject to the reporting person providing service through the applicable vesting date. |
| 2 | Derivative | Option (right to buy) | 2025-06-09 | A | A | 43,750 | $0.00 | 43,750 | D | $12.47 · — to 2035-06-08 | 43,750 Common Stock | (F2) 25% of the option shares will vest on June 9, 2026, with the remaining option shares to vest in equal monthly installments over the following thirty-six months, subject to the reporting person providing service through the applicable vesting date. |